ArticleJournal of Korean medical science2026
Immunochemical Markers and Quality of Life in Severe Atopic Dermatitis: A Real-World Analysis.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere atopic dermatitis (AD) impacts quality of life substantially, however the major clinical and immunologic contributors to this burden remain unclear. This study aimed to compare clinical and immunochemical profiles between patients with non-severe and severe AD and to identify key factors associated with QoL impairment in those with severe disease.
methodsA retrospective analysis was conducted on 371 patients diagnosed with AD from 2020 to 2023 at Kosin University Gospel Hospital. Patients were categorized according to Eczema Area and Severity Index (EASI) scores, with severe AD defined as EASI > 21. Clinical characteristics, immunologic markers, and Dermatology Life Quality Index (DLQI) scores were assessed. Multivariate regression was used to identify factors independently associated with DLQI.
resultsAmong all patients, 140 (37.7%) had severe AD. This group exhibited significantly higher EASI and DLQI scores, more widespread skin involvement, and increased skin infections. Laboratory findings showed elevated total IgE, eosinophil counts, and specific IgE to
conclusionClinical severity and immunologic activity were associated with QoL in patients with severe AD. Total IgE, specific IgE to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.